CID-103

DRUG3 trials

Sponsors

CASI Pharmaceuticals, Inc., CASI pharmaceuticals, Inc.

Conditions

Antibody Mediated RejectionChronic Immune ThrombocytopeniaMultiple Myeloma

Phase 1

CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma

CompletedNCT04758767

CASI Pharmaceuticals, Inc.Multiple Myeloma

Start: 2021-03-22End: 2023-01-19Updated: 2025-04-03

A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia

RecruitingNCT07017725

CASI Pharmaceuticals, Inc.Chronic Immune Thrombocytopenia

Start: 2025-01-03End: 2026-12-30Target: 75Updated: 2025-06-12

A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR).

RecruitingNCT07641426

CASI pharmaceuticals, Inc.Antibody Mediated Rejection

Start: 2026-06-09End: 2030-12-01Target: 58Updated: 2026-07-22

Related Papers

A dose-escalation and safety study of CID-103 followed by a randomized, open-label, parallel-arm multi-dose study evaluating the efficacy and tolerability of CID-103 in adults with persistent or chronic immune thrombocytopenia

Blood2025-11-03